Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


12 to 15 peptide repeating units in known peptide chain

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

514002000 - Peptide containing (e.g., protein, peptones, fibrinogen, etc.) DOAI

Patent class list (only not empty are listed)

Deeper subclasses:

Entries
DocumentTitleDate
20100016239HEPARIN BINDING MOTIF AND USE THEREOF - A method for reducing cytotoxicity of eosinophil derived toxins comprising administering to a subject an effective amount of heparin, heparan sulfate, a potent heparanase inhibitor or a polypeptide which has sequence as follows: BZBXBX, XBBBXXBX, XBBXBX, BBXXBBBXXBB, BXBBXB, XBBBXXBBBXXBBX, or TXXBXXTBXXXTBB, wherein X represents any amino acid, Z represents an aromatic amino acid, and B represents a basic amino acid and T represents a turn.01-21-2010
20100137221PEPTIDES THAT INTERACT WITH TOPOISOMERASE I AND METHODS THEREOF - Disclosed are compositions and methods for treating cancer comprising peptides that can act synergistically with chemotherapeutic agents.06-03-2010
20090192091Peptide inhibitors of protein kinase C - PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.07-30-2009
20100016236Osteogenic synthetic peptides, pharmaceutical compositions comprising the same, and medium containing the same - Disclosed herein is an osteogenic synthetic peptide, derived from bone morphogenetic protein-7, consisting of a sequence of 15 amino acid residues. Provided are also a pharmaceutical composition and a medium composition comprising the same. Having remarkable activity related to promoting osteoblast differentiation, the osteogenic synthetic peptide is very useful in the treatment of osteoporosis, bone defects and/or osteoarthritis.01-21-2010
20100048488IMMUNOMODULATORY PEPTIDES - The invention relates to peptides which, in some embodiments, bind to human FcRn and inhibit binding of the Fc portion of an IgG to an FcRn, thereby modulating serum IgG levels. The disclosed compositions and methods may be used in some embodiments, for example, in treating autoimmune diseases and inflammatory disorders. The invention also relates, in further embodiments, to methods of using and methods of making the peptides of the invention.02-25-2010
20090186824NOVEL PEPTIDES FOR TREATING AND PREVENTING IMMUNE-RELATED DISORDERS, INCLUDING TREATING AND PREVENTING INFECTION BY MODULATING INNATE IMMUNITY - In one aspect, the present invention provides isolated novel peptides that can be used to modulate innate immunity in a subject and/or for the treatment of an immune-related disorder, including treating and preventing infection by modulating innate immunity. Also provided are an agent reactive with the peptide, a pharmaceutical composition that includes the peptide, an isolated nucleic acid molecule encoding the peptide, a recombinant nucleic acid construct that includes the nucleic acid molecule, at least one host cell comprising the recombinant nucleic acid construct, and a method of producing the peptide using the host cell. The present invention further provides a method for treating and/or preventing infection in a subject by administering the peptide of the invention to the subject, thereby modulating innate immunity in the subject. Additionally, the present invention provides a method for predicting whether a subject would be responsive to treatment with a peptide of the invention.07-23-2009
20100035821Amide Linkage Cyclic Natriuretic Peptide Constructs - Cyclic constructs which bind to a natriuretic peptide receptor and include a plurality of amino acid residues, at least one amino acid surrogate of formula I:02-11-2010
20100041613NOVEL ANTIBIOTIC COMPOSITIONS - This invention is directed to antibiotic compositions comprising a targeting moiety covalently linked to an antibiotic moiety. This invention is also directed to pharmaceutical compositions comprising the antibiotic compositions of the invention and methods of making and using the antibiotic compositions of the invention.02-18-2010
20090156504METHODS OF TREATING BLOOD CELL DEPLETION - Provided herein are methods and compositions useful for the replenishment of blood cells in a mammal after exposure to therapeutic radiation or drugs. Radiation illness can be reduced in animals by treatment with substance P analogs. In one embodiment, granulocytes can be regenerated after therapeutic radiation by the administration of a substance P analog. In one embodiment, substance P analogs are useful for reducing PARP activity or PARP expression. In one embodiment, substance P analogs are useful for preventing, reducing or ameliorating adverse effects of drugs. In one embodiment, drug induced blood dyscrasias can be ameliorated by the methods and compositions provided herein.06-18-2009
20090156505SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE-AMPHIPHILE NANOFIBERS - Peptide-amphiphilic compositions capable of self-assembly into useful nanostructures.06-18-2009
20100105625Product and Methods for Diagnosis and Therapy for Cardiac and Skeletal Muscle Disorders - Disclosed are products and methods to promote myoblast activation and cardiac and skeletal muscle growth or regeneration, and to treat heart and skeletal muscle diseases, based on the identification of cellular processes affected by prelamin A processing.04-29-2010
20090124555USE OF HISTOGRANIN AND HISTOGRANIN-LIKE COMPOUNDS AS INHIBITORS OF P2X7 RECEPTOR FUNCTION AND AS ANTI-ARTHRITIC AGENTS - The invention relates to the use of Histogranin-like compounds to reduce P2X05-14-2009
20090042804NOVEL PEPTIDE AMPHIPHILES HAVING IMPROVED SOLUBILITY AND METHODS OF USING SAME - Disclosed herein are novel peptide amphiphile molecules and compositions discovered to possess improved solubility in aqueous buffers which, in turn, facilitates purification required for pharmaceutical applications, particularly for in vivo administration to human patients. In addition, gels of such peptide amphiphile compositions are shown herein to possess unexpectedly superior gelation kinetics and rheological properties, including an increased mechanical stiffness, which better mimics the mechanical properties of natural central nervous system tissues.02-12-2009
20100130432Non-Natural Amino Acids and Neurotensin Analogues Thereof - This invention relates to non-natural desamino amino acid compounds, methods of making, and peptides containing these compounds as their N-terminus moieties. A preferred example is neurotensin (8-13) in which the N terminus is an alpha desamino N,N dimethyl homolysine residue.05-27-2010
20100130431DISCORDANT HELIX STABILIZATION FOR PREVENTION OF AMYLOID FORMATION - The invention is based on the discovery that the presence of a discordant helix in a protein or peptide is predictive of that protein or peptide's ability to form amyloid. The invention includes methods for detecting discordant helices and methods of screening for compounds that stabilize the α-helix of a discordant helix-containing polypeptide. Compounds discovered using these methods are useful for treating or preventing disorders in which amyloid is produced. Such disorders include Alzheimer's disease and prion-associated disorders.05-27-2010
20090305994Compounds Modulating Vegf Receptor and Uses Thereof - The present invention is related to the use of compounds which bind to the Vascular Endothelial Growth Factor Receptors and modulate the angiogenic response. The compounds, which mimic the VEGF amino acid region 17-25 involved in receptor recognition thereby inhibiting or stimulating the angiogenic process, can be used in the treatment of diseases characterized by excessive or defective angiogenesis VEGF-dependent, such as chronic ischemia, cancer, proliferative retinopathy and rheumatoid arthritis, states or conditions benefiting from the formation or regeneration of new vessels, as well as in the diagnosis of pathologies which present a overexpression of VEGF receptors or as biochemical tools to analyze the cellular pathways dependent on VEGF receptor activation.12-10-2009
20090111754Selective Inhibitors of Nuclear Factor KappaB Activation and Uses Thereof - The present invention provides cell permeable NF-κB inhibitors consist of a polypeptide derived from the p65 subunit of NF-κB and a protein transduction domain derived from antennapedia third helix sequence. The inhibitor suppressed NF-κB activation induced by TNF, LPS, IL-1, okadaic acid, PMA, H04-30-2009
20090105152METASTIN DERIVATIVES AND USE THEREOF - The present invention provides stable metastin derivatives having excellent biological activities (a cancer metastasis suppressing activity, a cancer growth suppressing activity, a gonadotrophic hormone secretion stimulating activity, sex hormone secretion stimulating activity, etc.). By substituting the constituent amino acids of metastin with specific amino acids in the metastin derivative of the present invention, blood stability, solubility, etc. are more improved, gelation tendency is reduced, pharmacokinetics are also improved, and an excellent cancer metastasis suppressing activity or a cancer growth suppressing activity is exhibited. Furthermore, the metastin derivative of the present invention has the effects of suppressing gonadotropic hormone secretion, suppressing sex hormone secretion, etc.04-23-2009
20090270333Methods of using motilin homologs - The present invention is directed to polynucleotides, polypeptides and peptide fragments thereof, and uses thereof for a novel cDNA sequence which has homology to motilin. Tissue distribution of the mRNA for the novel polypeptide is specific to the stomach, small intestine and pancreas. The present invention further includes agonists, antagonists, antibodies, host cells expressing the cDNA encoding the novel motilin homologs and methods for increasing gastric motility using the novel molecules.10-29-2009
20090069243NATRIURETIC ACTIVITIES - This document provides methods and material related to natriuretic polypeptides. For example, substantially pure polypeptides having a natriuretic peptide activity, nucleic acids encoding polypeptides having a natriuretic peptide activity, host cells containing such nucleic acids, and methods for inducing a natriuretic or diuretic activity within a mammal are provided.03-12-2009
20090012003POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.01-08-2009
20100184694T-140 PEPTIDE ANALOGS HAVING CXCR4 SUPER-AGONIST ACTIVITY FOR CANCER THERAPY - The present invention is directed to novel therapeutic uses of T-140 analog peptides and compositions comprising same. Specifically, the invention provides compositions and methods useful in cancer therapy.07-22-2010
20090012002COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING PEPTIDES, USES AND TREATMENT PROCESSES - The present invention has as an aim a cosmetic and/or dermatological and/or pharmaceutical composition comprising, as an active ingredient, at least a peptide of sequence X01-08-2009
20100216722USE OF THE PEPTIDE PRO-GLY-THR-CYS-GLU-ILE-CYS-ALA-TYR-ALA-ALA-CYS-THR-GLY-CYS AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pro-Gly-Thr-Cys-Glu-Ile-Cys-Ala-Tyr-Ala-Ala-Cys-Thr-Gly-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.08-26-2010
20080293641BIOLOGICALLY ACTIVE PEPTIDES - Thirty substantially pure and biologically active peptides are disclosed. Nucleic acids that have sequences coding for the biologically active peptides and pharmaceutical formulations produced therefrom are also disclosed.11-27-2008
20100029572Neurotrophic Peptides - The present invention relates to a neurotrophic peptide having an amino acid sequence selected from the group consisting of VG-DGGLFEKKL (SEQ ID No. 1), EDQQVHFTPTEG (SEQ ID No. 2) and IPENEADGMPATV (SEQ ID NO. 3).02-04-2010
20100125056CRYSTALLINE FORM OF LINACLOTIDE - The present invention relates to crystalline forms of linaclotide, as well as to various methods and processes for the preparation and use of the crystalline forms.05-20-2010
20100016237Novel Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.01-21-2010
20100120695POLYPEPTIDES THAT BIND MEMBRANE PROTEINS - Polypeptides which bind to the helical transmembrane region of membrane proteins are disclosed, as are methods for the design of polypeptides that bind to the transmembrane region of membrane proteins. Also provided are methods for the use of the disclosed polypeptides in various applications, as well as products made through the practice of the instant methods.05-13-2010
20090088388Peptides for Use In Treating Obesity - Novel cyclic and linear peptides of the formula R04-02-2009
20090088389NOVEL X-CONOTOXIN PEPTIDES (-II) - An isolated, synthetic or recombinant χ-conotoxin peptide having the ability to inhibit neuronal amine transporter comprising the following sequence of amino acids: Cys Cys Gly Tyr Lys Leu Cys Xaa5 Xaa6 Cys, SEQ ID NO: 3, where Xaa5 and Xaa6 are independently absent or represent any amino acid residue except Cys; or a sequence in which Gly, Tyr, Lys or Leu are subject to conservative amino acid substitution or side chain modification with the proviso that the peptide is not Mr1A, Mr1B, Mar2, CMrV1A, Bn1.5, Mr1.3 or Au1.4; or a salt, ester, amide, prodrug or cyclised derivative thereof.04-02-2009
20080207522Antimicrobial Peptides - A novel class of peptides having antimicrobial activity is provided. Also provided are methods for inhibiting the growth of bacteria utilizing the peptides of the invention. Pharmaceutical compositions comprising the novel class of peptides are also provided.08-28-2008
20090286743Methods and Compositions for Treating Conditions of the Eye - Provided are methods and compositions for the photodynamic therapy (PDT) of ocular conditions characterized by the presence of unwanted choroidal neovasculature, for example, neovascular age-related macular degeneration. The selectivity and sensitivity of the PDT method can be enhanced by combining the PDT with an anti-angiogenesis factor, for example, angiostatin or endostatin, or with an apoptosis-modulating factor. Furthermore, the selectivity and sensitivity of the PDT may be further enhanced by coupling a targeting moiety to the photosensitizer so as to target the photosensitizer to choroidal neovasculature.11-19-2009
20080274978Peptides That Antagonize Fpr Class Receptor Mediated Signaling - The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.11-06-2008
20080274979TREATMENT OF LEAKY OR DAMAGED TIGHT JUNCTIONS AND ENHANCING EXTRACELLULAR MATRIX - Self assembling peptides and peptidomimetics can be utilized for the treatment and support of disorders associated with leaky or damaged tight junction and weak, diseased, or injured extracellular matrix. The self-assembling materials generally have alternating hydrophilic or hydrophobic residues or hydrophobic and/or hydrophilic sections which allow the material to react or interact with the glycoproteins found in the ECM. Diseases in which treatment with these materials applied to or near the site in need of treatment include diabetic retinopathy, sepsis, burns, and certain neurodegenerative diseases such as Parkinson's and Alzheimer's. The formulations can be administered by injection, spraying, topically or by catheter or via a wound dressing or other material to which it is applied and then applied to the site in need of treatment.11-06-2008
20080280833Therapeutic Peptides Derived from Urokinase Plasminogen Activator Receptor - The present invention relates to a chemotactically active epitope derivable from the urokinase receptor, a mutated peptide that acts as an inhibitor of chemotaxis, and their therapeutic use.11-13-2008
20090247466NEUROPROTECTIVE INTEGRIN-BINDING PEPTIDE AND ANGIOPOIETIN-1 TREATMENTS - The present invention provides therapeutic compositions, kits and methods for treating nervous system injury in a mammal. Certain methods include administering to a mammal in need of such therapy an effective amount of angiopoietin-1 (Ang-1), or a functional analog thereof. Certain methods include administering a peptide having 4 to 20 amino acids that comprises an YVRL (SEQ ID NO:1) motif that may have activity at the αvβ3 or α5β1 integrin receptor, such as C-16, or a compound that is an agonist at the αvβ3 and/or α5β1 integrin receptor, which administration may be in combination with administration of Ang-1, or a functional analog thereof.10-01-2009
20080306007AGENTS FOR PROPHYLAXIS OR TREATMENT OF NEUROLOGICAL RELATED DISEASES AND CONDITIONS - Inhibitors of syndapin I binding to dynamin I (DynI) are provided. Examples include mimetics of a region of DynI including the serine residues S774 and S778 or phosphorylatable amino acids in homologous positions. Typically, the mimetics exclude or do not imitate at least one phosphorylation site provided by the serine residues or phosphorylatable amino acids. Peptide fragment inhibitors comprising or consisting of this region of DynI are also described. The inhibitors have application in the prophylaxis or treatment of neurological diseases or conditions. The inhibitors can also be used to inhibit neuronal cell vesicle trafficking and synaptic signal transmission.12-11-2008
20090264370POLYPEPTIDES HOMOLOGOUS TO VEGF AND BMP1 - The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF including conservation of the amino acids required for activity of VEGF. VEGF-E can be useful in wound repair, as well as in the generation and regeneration of tissue.10-22-2009
20100137223NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS AND USES THEREOF - Provided herein are neuropeptide-2 receptor agonists of the formula (I):06-03-2010
20100137222Basic Peptides and Their Use as Combined Antibacterial-Antifungine Agents - The invention relates to peptides, and peptide variants thereof, in which substantially all of the amino sequence of said peptide are the same, for use in the treatment of a mixed microbial infection.06-03-2010
20090137483Antagonists of the bradykinin B1 receptor - The present invention relates to composition of matter involving bradykinin B1 receptor antagonist peptides conjugated to a univalent vehicle, including peptides conjugated to univalent PEG. These compositions can be used as therapeutics or prophylactics against diseases or conditions, such as inflammation or pain, linked to the bradykinin B1 receptor.05-28-2009
20090137482BIOLOGICALLY ACTIVE PEPTIDE AND AGENT CONTAINING THE SAME - A peptide having any one of the amino acid sequences of SEQ ID NO: 1 or 13, preferably a peptide having any one of the amino acid sequences of SEQ ID NOS: 2 to 9 or a peptide having any one of the amino acid sequences of SEQ ID NOS: 10 and 15 to 17, is used as an active ingredient of an agent for promoting growth or differentiation of cells such as osteoblasts, chondroblasts, cementoblasts, bone marrow-derived mesenchymal stem cells and periodontal ligament-derived cells.05-28-2009
20090005317Methods for treating a corneal disorder and promoting skin wound healing - A method for treating a corneal disorder or for promoting skin wound healing comprising administering to a patient in need thereof a composition containing pharmaceutically effective amounts of (i) a first peptide comprising an amino acid sequence containing the following consecutive amino acids: Ser-Ser-Ser-Arg (SEQ ID NO: 1), or an analog thereof or a pharmaceutically acceptable salt thereof and (ii) a second peptide comprising an amino acid sequence containing the following consecutive amino acids with a terminal —NH01-01-2009
20080318868Use of Mycobacterial Mannosylated Lipoglycans Peptide Mimotopes For Treating Inflammation - The present invention is based on the discovery that biological peptide-based mimotopes of mannose-containing cell-wall compounds of 12-25-2008
20080234202Non-natural amino acids and neurotensin analogues - This invention relates to methods of synthesis of amino acid analogs contained within peptide sequences that is adapted for preparation of peptides containing analogs of basic amino acids lysine and arginine.09-25-2008
20090325884Method for Detecting Autoantibodies Formed in Rheumatoid Arthritis - Autoantibodies reacting against citrullinated peptides derived from C-telopeptides of type I and type II collagens are found in patients with rheumatoid arthritis. They detect sequences —YYXA from α1 or —FYXA from α2 chain of type I collagen or —YMXA from α1 chain of type II collagen, where X is citrulline. The antibodies are different from anti-filaggrin antibodies. The peptides of the invention can be used in diagnosis of rheumatoid arthritis. Oral administration of citrullinated peptides can induce tolerance and lead to the treatment of rheumatoid arthritis.12-31-2009
20090054344ANTI-ANGIOGENIC PROTEINS AND FRAGMENTS AND METHODS OF USE THEREOF - Proteins with anti-angiogenic properties are disclosed, and fragments thereof, and methods of using those proteins and fragments to inhibit or promote angiogenesis.02-26-2009
20090062207Methods and compositions for the treatment of gastrointestinal disorders - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.03-05-2009
20090203619Artificial platelets - Therapeutic agents suitable for use as artificial platelets are described. The agents comprise a fibrinogen binding precursor bound to an insoluble carrier, wherein the fibrinogen binding precursor can be converted by a wound site specific agent, such as thrombin, to a fibrinogen binding component bound to the carrier. The fibrinogen binding component has increased ability to bind fibrinogen compared to the fibrinogen binding precursor. The agents may be used to treat patients with deficiencies in their own platelets, such as hereditary or acquired defects of platelet numbers (thrombocytopenia) or function (thrombasthenia).08-13-2009
20090105151AMPHIPATHIC ALPHA-HELICAL PEPTIDE COMPOSITIONS AS ANTIVIRAL AGENTS - The invention features methods and compositions that exploit the ability of amphipathic alpha-helical (AH) peptides to cause disruption of lipid-containing vesicles, such as enveloped viruses, in a size-dependent manner.04-23-2009
20090105150Angiotensin derivatives - An angiotensin derivative comprising at least one angiotensin peptide moiety coupled to a peptide carrier-binding moiety which can be used for therapy and prophylaxis of conditions associated with the renin activated angiotensin system.04-23-2009
20090247467PEPTIDE EPITOPES OF VEGFR-2/KDR THAT INHIBIT ANGIOGENESIS - The disclosure provides antigenic peptides of Vascular Endothelial Growth Factor Receptor 2(VEGFR-2)/KDR. Pharmaceutical compositions including the peptides and/or antigen presenting cells that exhibit the VEGFR-2/KDR peptides on their cell surface are also provided. Methods for eliciting an immune response and for inhibiting angiogenesis by administering such pharmaceutical compositions are provided.10-01-2009
20090203618Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification - The present invention refers to analog compounds of peptides having the amino acid sequences SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4, including analgesic peptides derived from snakes of species such as 08-13-2009
20090253634Methods and Compositions for the Treatment of Gastrointestinal Disorders - The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastnoesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g. constipation associated with use of opiate pain killers, post-surgical constipation (post-operative ileus), and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.10-08-2009
20100016238Peptides for Use in the Treatment of Obesity - The present invention relates to novel peptide compounds which are effective in modulating one or more melanocortin receptor types, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of obesity as well as a variety of diseases or conditions associated with obesity.01-21-2010
20090275521Regulation of Microphage Migration Inhibitory Factor (MIF) Activity - The present invention relates to modulating, neutralizing, or inactivating the activity of migration inhibitory factor (MIF). In particularm, the present invention provides methods for modulating, neutralizing, or inactivating MIF activity by complexing MIF with other molecules, preferably a protein, that is capable of associating with MIF. These molecules can be used for treating diseases by the regulation of MIF activity.11-05-2009
20100184695VASCULAR ENDOTHELIAL CELL-BINDING PEPTIDE - A peptide consisting of an amino acid sequence represented by any one of SEQ ID Nos. 1 to 76 of the present invention, a peptide consisting of an amino acid sequence in which one or several amino acids are substituted, deleted, inserted or added in these amino acid sequences, and having an ability to bind to, or to be taken into an activated vascular endothelial cell, or a peptide containing the above peptide as a partial sequence, and having an ability to bind to, or to be taken into an activated vascular endothelial cell is a novel peptide ligand specifically binding to a neovascular endothelial cell, and such a ligand can be effectively used for treating and diagnosing a disease accompanying vascularization such as a solid tumor.07-22-2010
20100184698USE OF A DESLORELIN AND MASTOPARAN AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Pyr-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-NHEt optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.07-22-2010
20100184697PEPTIDE-BASED STAT INHIBITOR - A peptide or peptidomimetic comprising the amino acid sequence of the second helix of a STAT protein, or a variant of such sequence, wherein the peptide or peptidomimetic comprises about 40 or fewer amino acids and binds to a STAT protein, as well as a method of inhibiting a STAT protein in a cell, a method of treating or preventing a disease associated with STAT overexpression in a host, and related compounds, compositions, and methods.07-22-2010
20100184696Peptides and Their Use - The present invention relates to peptides for use as antifungal agents. The peptides comprise a sequence of 5 to 15 basic amino acids wherein substantially all of the amino acids in said sequence are the same.07-22-2010
20080214469Novel Biologically Active Peptides and Their New Uses - Novel peptides are disclosed with their use as a pharmaceutical composition. A method is also disclosed for making pharmaceutical compositions and treatment of an individual.09-04-2008
20100240592TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 α-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as 09-23-2010
20100222280PEPTIDES WITH THE CAPACITY TO BIND TO TRANSFORMING GROWTH FACTOR beta 1 (TGF-beta 1) - The described peptides possess the capacity to bind to Transforming Growth Factor TGF-β1 (TGF-β1), and are potential inhibitors of the biological activity of TGF-β1 through direct binding to this cytokine. These peptides can be used in the treatment of diseases or pathological alterations based on excessive or deregulated TGF-β1 expression, e.g., liver fibrosis, pulmonary fibrosis, corneal fibrosis and haze.09-02-2010
20090075899Inhibiting collagen-induced platelet aggregation and activation with peptide variants - The present invention provides peptides consisting of L- and/or D-amino acids and combinations thereof, which affect platelets by action on the collagen receptor, glycoprotein VI (GPVI). More specifically, however, the peptides act on the GPVI-FcRγ signaling complex. The invention also provides lipid and sugar conjugated peptides comprising L- or D-amino acids. The invention still further provides a method of designing of the peptides and lipid- and/or sugar-conjugated peptides comprising L- or D- amino acids. The present invention further relates to the therapy of various disease states involving the use of these peptides and compounds. Specifically, the peptides and compounds are useful in the treatment and/or prevention of a disease or condition involving platelet activation and aggregation, and more particularly, collagen-induced platelet activation and aggregation. They also are useful in the production of medical devices comprising peptide matrices (i.e., for example, cardiovascular stents).03-19-2009
20100210559TRAP-14 AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pm-Phe-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ser-Phe-Leu-Leu-Arg-Asn-Pro-Asn-Asp-Lys-Tyr-Glu-Pro-Phe-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.08-19-2010
20080293640Polypeptide inhibitors of HSP27 kinase and uses therefor - The present invention provides polypeptide inhibitors of HSP27 kinase, compositions thereof, and methods for using such polypeptides and compositions for various therapeutic uses.11-27-2008
20100204137THE USE OF SUBSTANCES FOR THE TREATMENT OF LOSS OF EYESIGHT IN HUMANS WITH GLAUCOMA AND OTHER DEGENERATIVE EYE DISEASES - Methods for the prevention and treatment of ocular disorders, in particular glaucoma, through blocking the toxic effects of β-amyloid (Aβ) derivatives, and pharmaceutical compositions for effecting such prevention and treatment thereof.08-12-2010
20100197602USE OF FOLLICULAR GONADOTROPIN RELEASING PEPTIDE AS A THERAPEUTIC AGENT IN THE TREATMENT OF STREPTOCOCCUS PNEUMONIAE INFECTION - The present invention is directed to the use of the peptide compound Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Thr-Asp-Thr-Ser-His-His-Asp-Gln-Asp-His-Pro-Thr-Phe-Asn-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.08-05-2010
20100056457Zinc Finger Binding Domains for CNN - Polypeptides that contain zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula CNN are provided. Compositions containing a plurality of polypeptides, polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides, compositions and polynucleotides are also provided.03-04-2010
20090221509Tumour-associated peptides binding to MHC-molecules - The invention relates to a tumour-associated peptide with an amino acid sequence that is selected from the group consisting of SEQ ID-No. 1 to SEQ ID-No. 101 of the attached sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major-histocompatibility-complex (MHC) class-I. In addition, the invention relates to the use of the peptides and the nucleic acids encoding for the peptides for the production of a medicament, and for the treatment of tumorous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that has at least one of the peptides.09-03-2009
20090042803INHIBITORS OF PROTEIN KINASES AND USES THEREOF - Compounds that are capable of inhibiting the activity of one or more protein kinases are provided. The compounds are short, predominantly basic peptidic compounds comprising between about 5 and about 20 amino acids, and can optionally comprise an ATP mimetic moiety. The protein kinase inhibiting compounds can be used to inhibit the activity of one or more protein kinases in vitro or in vivo. Also provided are methods of inhibiting a protein kinase in a subject by administration of an effective amount of a protein kinase inhibiting compound and the use of the protein kinase inhibiting compounds, alone or in combination with other chemotherapeutic agents, in the treatment of protein kinase mediated diseases and disorders.02-12-2009
20100056458Peptides Inhibiting Angiotensin-Converting Enzyme - The invention provides novel peptides having ACE-inhibiting properties derived from milk proteins, as well as their mixtures and their use as hypotensive aids. The peptides have from 2 up to 14 amino acid residues, at least one of which is a branched-chain amino acid. Examples include IV, LV, VLGPV, VPYPQ, VPYPQR, AVP, KIHP, KYKVPQL, FFVAPFPEVFG, VAPFPEVF, MKGLDI, KGLDI, LR, MHIRLS, MHI, IIA, IAEKT, LKALP, ALP and KK. The invention also provides a process of producing the peptide by enzymatic hydrolysis of milk proteins or other proteins.03-04-2010
20100056459Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway - The invention provides cell-permeable peptides that selectively block the branch of the JNK signaling pathway controlled by the islet-brain (IB) proteins. The provided cell-permeable peptides block the binding of intermediate kinases in the c-Jun amino terminal kinase (JNK) signaling pathway, thereby decreasing the downstream effects of c-Jun amino terminal kinase (JNK).03-04-2010
20080249026PEPTIDES AND THEIR UTILITY IN MODULATION OF BEHAVIOR OF CELLS EXPRESSING alpha3beta1 INTEGRINS - The present invention relates to a peptide comprising the sequence R10-09-2008
20100069307NEUROPEPTIDE-2 RECEPTOR (Y-2R) AGONISTS - Provided herein are neuropeptide-2 receptor agonists of the formula (I):03-18-2010
20090118194Measurement of melanocortin peptides and uses thereof - The present invention relates to melanocortin peptides and to methods that utilise melanocortin peptides, their measurement, their receptors and biological response systems for the risk assessment and diagnosis of disease. The biological response systems are also utilised to screen for compounds that act as agonists or antagonists of melanocortin receptors.05-07-2009
20080242617Two component bacillus lantibiotic and methods for producing and using the same - The present invention relates to two-component lantibiotics isolated from 10-02-2008
20100210558MINIGASTRIN AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH08-19-2010
20100113366USE OF PROLINE-RICH PEPTIDE DERIVED FROM HYPOTHALAMUS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PROPHYLAXIS OF CATTLE LEUCOSIS - The invention concerns to the medicinal preparation containing peptides and may be used for the treatment and/or prophylaxis of cattle leucosis.05-06-2010
20090203620METHODS FOR ATTENUATING RELEASE OF INFLAMMATORY MEDIATORS AND PEPTIDES USEFUL THEREIN - The present invention includes methods of inhibiting or suppressing cellular secretory processes. More specifically the present invention relates to inhibiting or reducing the release of inflammatory mediators from inflammatory cells by inhibiting the mechanism associated with the release of inflammatory mediators from granules in inflammatory cells. In this regard, the present invention discloses an intracellular signaling mechanism that illustrates several novel intracellular targets for pharmacological intervention in disorders involving secretion of inflammatory mediators from vesicles in inflammatory cells. Peptide fragments and variants thereof of MANS peptide as disclosed in the present invention are useful in such methods.08-13-2009
20100190719PEPTIDES AS ANTIMICROBIAL AGENTS TOWARDS CAMPYLOBACTER SPP - The present invention relates to peptides that exhibit antimicrobial properties towards 07-29-2010
20100190720Compositions and Methods for Preventing or Treating Cancer - The present invention relates to a MUC1 cytoplasmic tail peptide or portion thereof. These peptides are useful for inducing an immune response to MUC1-expressing tumor cells and thus for preventing or treating cancer.07-29-2010
20090253635PEPTIDES AND PEPTIDOMIMETICS HAVING ANTI-PROLIFERATIVE ACTIVITY AND/OR THAT AUGMENT NUCLEIC ACID DAMAGING AGENTS OR TREATMENTS - This invention provides compounds including peptides and peptidomimetics that can be used to treat cell proliferative disorders, such as those associated with benign and malignant tumor cells. While the invention is not limited to any particular mechanism, the compounds of the invention appear to function at least in part by inhibiting G2 cell cycle checkpoint. Thus, invention compounds can be used to inhibit cell growth alone or be used in combination with a nucleic acid damaging treatment to inhibit cell growth.10-08-2009
20090318363Peptide Aptamer for Neutralizing the Binding of Platelet Antigene Specific Antibodies and Diagnostic and Therapeutic Applications Containing the Same - The present invention relates to a peptide aptamer which mimics particularly the human platelet antigene HPA-Ia epitope present on the platelet GPIIb/IIIa molecules and which is capable of neutralizing the binding of HPA-I a specific antibodies (anti-HPA-1 a). This peptide aptamer is advantageously used in a method for detecting and identifying HPA-I a specific antibodies in human serum, in a diagnostic kit for screening and identifying antibodies, in an immunoassay and a pharmaceutical composition.12-24-2009
20100216721Inhibition of HIV-1 Infection by Potent Metallocene Conjugated Peptide Through Conformational Entrapment of Envelope GP120 - The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use.08-26-2010
20090170781Identification of Immunologically Effective Epitopes on the Surface of Red Blood Cells and Their Use in a Method of Inducing Tolerance Thereto - The present invention relates to a method of identifying an immunologically effective epitope, the method comprising: a) preparing an oligomer of a protein present on the surface of a red blood cell which includes a polymorphism therein and b) ascertaining whether the oligomer stimulates T-cells and a composition comprising an immunologically effective epitope for the tolerisation of a subject that has been exposed to an antithetical allele.07-02-2009
20100048487NOVEL CELL PENETRATING PEPTIDE - According to the present invention, it is possible to provide a novel cell penetrating peptide that transports proteins into cells and/or into nuclei at higher frequency than conventional cell penetrating peptides, and a pharmaceutical containing the peptide.02-25-2010
20100004179TARGETING OF EWS-FLI1 AS ANTI-TUMOR THERAPY - Peptides and compounds are provided that function as EWS-FLI1 protein inhibitors. The peptides and compounds have utility in the treatment of Ewing's sarcoma family of tumors. Also provided are methods of preparing the compounds and assays for identifying inhibitors of EWS-FLI1 protein.01-07-2010
20100197600USE OF THE PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALONE OR IN COMBINATION WITH THE PEPTIDE PRO-GLY-THR-CYS-GLU-ILE-CYS-ALA-TYR-ALA-ALA-CYS-THR-GLY-CYS-OH AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.08-05-2010
20100197601USE OF A FIBRINOGEN RECEPTOR ANTAGONIST AND/OR FOLLICULAR GONADOTROPIN RELEASING PEPTIDE AS A THERAPEUTIC AGENT IN THE TREATMENT OF STREPTOCOCCUS PNEUMONIA INFECTION - The present invention is directed to the use of the peptide compound Ac-Pen-Arg-Gly-Asp-Cys-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurode-generative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquide buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Ac-Pen-Arg-Gly-Asp-Cys-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.08-05-2010
20090131320PEPTIDES MODULATING THE ACTIVITY OF THE ENGRAILED TRANSCRIPTION FACTOR - The invention relates to peptides which can become fixed to the engrailed transcription factor and which can modulate the activity thereof.05-21-2009
20100048489Stable Solid Formulation of A GC-C Receptor Agonist Polypeptide Suitable for Oral Administration - Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.02-25-2010
20100009922HYPOTENSIVE PEPTIDES FROM SOY PROTEINS AND METHOD OF PREPARATION - A method for preparing an anti-hypertension peptide composition, using a microbe which is intrinsic to common soybean food and capable of producing protease. The composition mainly contain peptides with a molecular weight of less than 10 kD which are produced by decomposition of soy proteins by the microbe in a fermentation process. The composition is shown to have an ACE inhibitory activity and an effect of lowering blood pressure when administered to a mammalian subject.01-14-2010
20090318364METHOD AND PEPTIDE FOR REGULATING CELLULAR ACTIVITY - Method and peptide for regulating cellular activity includes a panel of synthesized peptides that have biological effects on inhibiting or enhancing cellular activity. Selected peptides can be used as therapy to reduce and/or inhibit, or initiate and/or enhance, an inflammatory response in a subject.12-24-2009
20100168032Smart Pro-Drugs of Serine Protease Inhibitors - The present invention relates to prodrugs of protease inhibitors, such as inhibitors of the proteosome, DPP IV, FAPα and the like. These “pro-inhibitors” are activated, i.e., cleaved, by an “activated protease” to release an active inhibitor moiety in proximity to a “target protease”. The identity of activating protease and target protease can be the same (such as pro-inhibitors being referred to as “Target-Activated Smart Protease Inhibitors” or “TASPI”) or different (e.g., “Target-Directed Smart Protease Inhibitors” or “TDSPI”). After activation of the pro-inhibitor, the active inhibitor moiety can self-inactivate by, e.g., intramolecular-cyclization or cis-trans isomerization.07-01-2010
20100168033UNACYLATED GHRELIN AS THERAPEUTIC AGENT IN THE TREATMENT OF METABOLIC DISORDERS - An isolated polypeptide comprising any amino acid fragment of unacylated ghrelin or any analog thereof, wherein the polypeptide has an activity selected from the group consisting of a) decreasing blood glucose levels; b) increasing insulin secretion an/or sensitivity; c) binding to insulin-secreting cells; and d) promoting survival of insulin-secreting cells. As well as the use of the polypeptide in the treatment of a disorder associated with impaired glucose metabolism.07-01-2010
20100168031Lat peptides and their use in assays for identifying immunosuppressants - The invention relates to novel peptides and their use in assays for identifying novel immunosuppressants. More particularly the present invention provides methods and compositions for identifying compounds that will modulate the interaction of protein tyrosine kinase substrates with their intracellular ligands, as well as between their intracellular ligands and other members of the signaling pathway.07-01-2010
20100204135USE OF LVV-HEMORPHIN-6 AND OPTIONALLY AF12198 AS THERAPEUTIC AGENT(S) - The present invention is directed to the use of the peptide compound Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-OH as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide Leu-Val-Val-Tyr-Pro-Trp-Thr-Gln-Arg-OH optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.08-12-2010
20100204134USE OF THE PEPTIDE HIS-SER-LEU-GLY-LYS-TRP-LEU-GLY-HIS-PRO-ASP-LYS-PHE ALONE OR IN COMBINATION WITH THE PEPTIDE GLY-ARD-GLY-ASP-ASN-PRO-OH AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Ser-Leu-Gly-Lys-Trp-Leu-Gly-His-Pro-Asp-Lys-Phe optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.08-12-2010
20100204136USE OF A PEPTIDE AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH08-12-2010
20100204133Irreversibly-inactivated pepsinogen fragment and pharmaceutical compositions comprising the same for detecting, preventing and treating HIV - An isolated antiviral peptide is characterized by the amino acid sequence GDEPLENYLDTEYF and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41 and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.08-12-2010
20090270334NEURONAL DIFFERENTIATION INHIBITOR PEPTIDE AND USE THEREOF - Disclosed is a neuronal differentiation inhibitor which comprises at least one peptide capable of inhibiting or controlling the neuronal differentiation of at least one cell capable of being differentiated into a neuronal cell. The peptide is an artificially synthesized peptide which comprises a BC-box derived amino acid sequence comprising at least 10 contiguous amino acid residues selected from an amino acid sequence constituting the BC-box of at least one protein belonging to the elongin A family or comprises an amino acid sequence having a partial modification in the BC-box derived amino acid sequence.10-29-2009
20100234302PEPTIDE FOR INDUCTION OF IMMUNE TOLERANCE AS TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS - The present invention relates to D-amino acid peptides and their use in methods for the diagnosis and/or treatment of immune disorders such as systemic lupus erythematosus.09-16-2010
20100210557USE OF RFRP, ALONE OR IN COMBINATION WITH NEUROKININ-B, AS A THERAPEUTIC AGENT - The present invention is directed to the use of the peptide compound Met-Pro-His-Ser-Phe-Ala-Asn-Leu-Pro-Leu-Arg-Phe-NH08-19-2010
20100173848Methods of inhibiting chemokine binding to chemokines receptors - Novel peptidic or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokine receptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.07-08-2010
20100173849NEO-TRYPTOPHAN - Methods of inducing antinociception in a human are described. The method includes the step of administering an effective dose of a polypeptide comprising L-neo-tryptophan to the human extracranially. The polypeptide containing L-neo-tryptophan could be, but is not limited to, NT64L, NT65L, NT66L, NT67L, NT69L, NT69L′, NT71, NT72, NT73, NT74, NT75, NT76, or NT77.07-08-2010
20080227717Potent compstatin analogs - Compounds comprising peptides and peptidomimetics capable of binding C3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.09-18-2008
20080227716Use of Peptides for Protecting Skin from Hair-Treatment Agents - The present invention relates to the use of short-chain peptides for the protection of the skin from hair-treatment agents, and particularly for the protection of the scalp from dyes or colorants.09-18-2008
20080221039Kinin Antagonists For Treating Bladder Dysfunction - The present invention is related to the use of a kinin receptor antagonist for the manufacture of a medicament for the treatment and/or prevention of bladder dysfunction, whereby the kinin receptor is selected from the group comprising B1 and B2 receptors.09-11-2008
20080221038Compounds for Control of Appetite - This invention relates generally to peptides including tripeptides and to methods for pharmaceutical treatment of mammals using such tripeptides and analogs thereof. More specifically, the invention is directed to neuropeptide Y (“NPY”) receptor antagonists and agonists including O-glycosylated tripeptides, i.e. O-glycopeptides, and extended tripeptides, and their analogs, as well as to PYY analogs, to pharmaceutical compositions containing such tripeptides and PYY analogs, and to methods of treatment of mammals using such tripeptides and PYY analogs. In addition, the invention relates to methods of treatment of mammals using such tripeptides and PYY analogs for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm.09-11-2008
20080200393Method and Composition For Treating Angiogenesis and For Preventing Cancer Progression and Metastasis Comprising a Prostate Secretory Protein (Psp94) Family Member - Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases as well as for preventing cancer progression and metastasis through the use of a prostrate secretory protein (PSP) family member.08-21-2008

Patent applications in class 12 to 15 peptide repeating units in known peptide chain